



Short version of press release from Emotra AB  
Gothenburg September 11, 2013

## Emotra issues new shares for 877 500 SEK

- *In clinical studies a strong relationship between hyporeactivity and risk for suicide has been demonstrated*
- *Emotra has developed, EDOR, ElektroDermal Orientation Reactivity, and objective and quantitative psychophysiological test for the measurement of hyporeactivity*
- *Evaluation of suicide risk is the most challenging problem for the psychiatric care to solve*

---

During the Annual General Meeting, June 27 2013, the Board of Emotra was authorized to decide on issues of new shares, without giving priority to the present shareholders, to be carried out not later than at the date of the next Annual General Meeting. This authorization was limited so that the share price must exceed 7,20 SEK and the number of shares were limited to 420 000.

Based on this authorization, the Board decided on the 10<sup>th</sup> of September 2013 to issue 65 000 new shares to three private investors, Göran Ofsén, 25 000 shares and Kristoffer and Björn Biberg, 20 000 shares each, at a share price of 13,50 SEK. Göran Ofsén became shareholder in Emotra during the issue of shares this last spring. Kristoffer and Björn Biberg have become shareholders since the share became listed for sale at AktieTorget. The share price has been decided after negotiations. The total number of shares in Emotra, thereby increases from 1 881 835 to 1 946 835.

Emotra is at present in a very dynamic phase and its activities involve an increasing number of clinical centers. All work is done in a small organization and in such a cost effective manner as possible, in order to minimize the financial risks. The now completed issue of new shares has been done in order to further strengthen the financial situation and to make possible even more offensive activities together with leading clinical teams in Europe.

When the support for EDOR from these clinical teams, is strong enough, the method will be launched in Europe. This can certainly happen before all clinics have completed their studies. CE-marking of the product will be finalized during the next six months.

The psychiatric care has relevant preventive actions and resources to use when risk for suicide has been identified. Unfortunately there are today no accurate methods for the identification of risk patients, with the use of EDOR this difficult diagnostic problem can be solved. The test does not take more than 15 minutes. With necessary preparations, the total time is 30 minutes. The introduction of EDOR as a clinical routine procedure has the potential to substantially reduce the number of suicides and suicide attempts in the world.

*For more information, please contact*

*Claes Holmberg, President and CEO, Emotra AB, Telephone: +46708254547, [claes@emotra.se](mailto:claes@emotra.se)*

---

**Emotra AB** is a Swedish medical device company focusing on research, development, clinical trials and marketing within the field of suicide prevention. The company's method, EDOR, is an objective and quantitative diagnostic psychophysiological test of hyporeactivity. During the test, the patients listen and react to a series of sound signals. The response is measured as minimal fluctuations in the dermal electrical conductivity and analyzed. With research and clinical documentation an extremely sensitive and accurate test, with the purpose of evaluating suicide risk, has been developed.

Emotra AB, Göteborgsvägen 74, 433 63 Sävedalen, Sweden

Telephone: +46 708 25 45 47, [www.emotra.se](http://www.emotra.se)